medac Pharma Products

Alacare®
5-aminolevulinic acid
Alacare® contains the active substance 5-aminolevulinic acid
It is available as a medicated plaster

Click here to view the Alacare® SPC

Carmustine ObviusCarmustine Obvius is available as a powder and solvent for concentrate for solution for infusion

Click here to view the Carmustine Obvius SPC

Chemosat® CHEMOSAT® is a delivery and filtration system for percutaneous hepatic perfusion
DacarbazineDacarbazine is available as a powder for solution for injection/infusion

Click here to view the Dacarbazine SPC

DoxorubicinDoxorubicin is available as a solution for infusion

Click here to view the Doxorubicin SPC

EpirubicinEpirubucin is available as a solution for injection

Click here to view the Epirubicin SPC

EtoposideEtoposide is available as a concentrate for solution for infusion

Click here to view the Etoposide SPC

FluorouracilFluorouracil is available as a solution for injection

Click here to view the Fluorouracil 25mg/ml SPC


Click here to view the Fluorouracil 50mg/ml SPC


Click here to view the direct healthcare professional communication:

I am a UK healthcare professional

Gliolan®
5-aminolevulinic acid
Gliolan® contains the active substance 5-aminolevulinic acid
Gliolan® is available as a powder for oral solution

Click here to view the Gliolan® SPC

HydroxycarbamideHydroxycarbamide is available as capsules

Click here to view the Hydroxycarbamide SPC

IrinotecanIrinotecan is available as a concentrate for solution for infusion

Click here to view the Irinotecan SPC

Leflunomide medac 15mg
Leflunomide
Leflunomide medac 15mg contains the active substance leflunomide
It is available as film-coated tablets

Click here to view the Leflunomide 15mg SPC


Click here to view the risk minimisation patient leaflet


Click here to view the risk minimisation physician leaflet

Levofolinic acid
Disodium Levofolinate
Levofolinic acid contains the active substance disodium levofolinate
It is available as a solution for injection/infusion

Click here to view the Levofolinic acid SPC

LomustineLomustine is available as capsules

Click here to view the Lomustine SPC

Methotrexate SolutionMethotrexate is available as a solution for injection

Click here to view the Methotrexate Solution SPC

Metoject® PEN
Methotrexate
Metoject® PEN contains the active substance methotrexate
It is available as a solution for injection in pre-filled pen

Click here to view the Metoject® PEN SPC

Mitomycin medac
Mitomycin
Mitomycin medac contains the active substance mitomycin
It is available as a powder and solvent for intravesical solution

Click here to view the Mitomycin medac SPC

OxaliplatinOxaliplatin is available as a concentrate for solution for infusion

Click here to view the Oxaliplatin SPC

PamidronatePamidronate is available as a sterile concentrate for solution for infusion

Click here to view the Pamidronate SPC


Click here to view the risk minimisation patient reminder card

Sodiofolin
Sodium Folinate
Sodiofolin contains the active substance disodium folinate
It is available as a solution for injection/infusion

Click here to view the Sodiofolin SPC

Spectrila®
Asparaginase
Spectrila® contains the active substance asparaginase

It is available as a powder for concentrate for solution for infusion

Click here to view the Spectrila® SPC

Trecondi®
Treosulfan
Trecondi® contains the active substance treosulfan
It is available as a powder for solution for infusion

Click here to view the Trecondi® SPC

TreosulfanTreosulfan is available as capsules

Click here to view the Treosulfan Capsules SPC

VinorelbineVinorelbine is available as a concentrate for solution for infusion

Click here to view the Vinorelbine SPC

For enquiries about any of our products, please contact the Medical Information Department on +44 (0)1786 458086 or email us at info@medacpharma.co.uk

Our normal enquiry service is available from 9am to 5pm Monday to Friday. However we do offer an emergency service outside these hours for urgent enquiries.

Apart from the desired effects, medical products can have side effects that are unpleasant or unintended. At medac, we continually collate information about side effects in order to monitor the benefit risk balance of each medication throughout its marketing lifecycle, and if necessary, can take action to better protect patient safety.

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to medac drug safety at drugsafety@medac.de

We may contact you to gain further details about the report. However we are unable to provide medical advice. If you are concerned about any aspect of your treatment please discuss this with your healthcare professional (such as a doctor, nurse or pharmacist).